肝硬化中医诊疗指南

中华中医药学会肝胆病分会

doi:10.12449/JCH240305

肝硬化中医诊疗指南

DOI: 10.12449/JCH240305

中华中医药学会肝胆病分会

基金项目:

国家中医药管理局高水平中医药重点学科建设项目 (zyyzdxk-2023005);

首都卫生发展科研专项 (CFH 2024-1-2173)

利益冲突声明：本指南由中华中医药学会立项，在中医临床诊疗指南制订专家总指导组和内科专家指导组的指导、监督下实施。制订过程与任何单位、个人无经济利益关系。

计量
- 文章访问数: 1112
- HTML全文浏览量: 348
- PDF下载量: 311
- 被引次数: 0
出版历程
- 收稿日期: 2024-02-07
- 录用日期: 2024-02-19
- 出版日期: 2024-03-20

Guidelines for traditional Chinese medicine diagnosis and treatment of liver cirrhosis

Branch of Hepatobiliary Diseases， China Association of Chinese Medicine

Research funding:

NATCM’s Project of High-level Construction of Key TCM Disciplines (zyyzdxk-2023005);

Capital’s Funds for Health Improvement and Research (CFH 2024-1-2173)

摘要

摘要: 近年来，随着基础与临床研究的进展，医务工作者对肝硬化的临床诊治有了进一步的认识。同时，国内关于肝硬化的中医证候规律、中西医结合治疗的研究日趋增多，尤其是在抗肝纤维化方面中医中药发挥了重要的作用。本指南在2008版《中医内科常见病诊疗指南》的基础上进行修订，项目组按照中医药标准化、循证医学、技术指导文件的相关要求，通过文献研究、专家访谈、问卷调查、临床问题确定、证据分级、推荐意见形成、征求意见等多种形式最终形成一套可行的中医药诊疗指南以切实、规范地指导临床诊疗。该指南经中华中医药学会批准发布，标准编号：T/CACM1576-2024。
- 肝硬化 /
- 中医 /
- 诊疗准则
Abstract: In recent years， with the advances in basic and clinical research， medical workers have gained a deeper understanding of the clinical diagnosis and treatment of liver cirrhosis， and meanwhile， more studies have been conducted on the traditional Chinese medicine （TCM） syndromes and integrated traditional Chinese and Western medicine treatment of liver cirrhosis in China， especially in the field of anti-liver fibrosis treatment where TCM plays an important role. This guideline is revised based on the 2008 edition of Guidelines for the diagnosis and treatment of common diseases in Chinese internal medicine， and in accordance with related requirements in TCM standardization， evidence-based medicine， and technical guidance documents， the project team formed the guidelines for TCM diagnosis and treatment through literature research， expert interview， questionnaire survey， identification of clinical problems， grading of evidence， formation of recommendation opinions， and soliciting opinions， so as to provide practical and standardized guidelines for clinical diagnosis and treatment. This guideline has been approved by China Association of Chinese Medicine， with the standard number of T/CACM1576-2024.
- Liver Cirrhosis /
- Traditional Chinese Medicine /
- Practice Guideline

HTML全文

表 1 GRADE证据等级分级表

Table 1. GRADE evidence grading system

证据质量	详细说明
高（A）	进一步研究不可能改变对该疗效评估结果的可信度
中（B）	进一步研究有可能影响该疗效评估结果的可信度，且可能改变该评估结果
低或极低（C）	进一步研究很有可能影响该疗效评估结果的可信度，且很可能改变该评估结果

下载: 导出CSV

参考文献(63)

[1]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
[2]	Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on clinical diagnosis and therapy of liver cirrhosis[J]. J Clin Hepatol, 2023, 39( 9): 2057- 2073. 中华医学会消化病学分会. 中国肝硬化临床诊治共识意见[J]. 临床肝胆病杂志, 2023, 39( 9): 2057- 2073.
[3]	D’AMICO G, GARCIA-TSAO G, PAGLIARO L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies[J]. J Hepatol, 2006, 44( 1): 217- 231. DOI: 10.1016/j.jhep.2005.10.013.
[4]	XIAO J, WANG F, WONG NK, et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective[J]. J Hepatol, 2019, 71( 1): 212- 221. DOI: 10.1016/j.jhep.2019.03.004.
[5]	RUNYON BA, AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012[J]. Hepatology, 2013, 57( 4): 1651- 1653. DOI: 10.1002/hep.26359.
[6]	European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69( 2): 406- 460. DOI: 10.1016/j.jhep.2018.03.024.
[7]	European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J]. J Hepatol, 2010, 53( 3): 397- 417. DOI: 10.1016/j.jhep.2010.05.004.
[8]	MOORE KP, WONG F, GINES P, et al. The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club[J]. Hepatology, 2003, 38( 1): 258- 266. DOI: 10.1053/jhep.2003.50315.
[9]	China Association of Chinese Medicine. Guidelines for diagnosis and treatment of common internal diseases in Chinese Medicine[M]. Beijing: China Press of Traditional Chinese Medicine, 2008: 133- 139. 中华中医药学会. 中医内科常见病诊疗指南[M]. 北京: 中国中医药出版社, 2008: 133- 139.
[10]	ZHANG LJ, SCHUPPAN D. Traditional Chinese Medicine(TCM) for fibrotic liver disease: Hope and hype[J]. J Hepatol, 2014, 61( 1): 166- 168. DOI: 10.1016/j.jhep.2014.03.009.
[11]	NAN YM, KONG LB. Advances in diagnosis and treatment of liver cirrhosis with integrated traditional Chinese and Western medicine[J]. Chin J Hepatol, 2018, 26( 5): 328- 331. DOI: 10.3760/cma.j.issn.1007-3418.2018.05.003. 南月敏, 孔令波. 肝硬化的中西医结合诊治进展[J]. 中华肝脏病杂志, 2018, 26( 5): 328- 331. DOI: 10.3760/cma.j.issn.1007-3418.2018.05.003.
[12]	JIANG SL, LIU P. Research advances in integrated traditional Chinese and Western medicine therapy for liver cirrhosis[J]. J Clin Hepatol, 2022, 38( 9): 1953- 1955. DOI: 10.3969/j.issn.1001-5256.2022.09.001. 蒋式骊, 刘平. 肝硬化中西医结合治疗的研究进展[J]. 临床肝胆病杂志, 2022, 38( 9): 1953- 1955. DOI: 10.3969/j.issn.1001-5256.2022.09.001.
[13]	China National Committee for Terminology in Science and Technology. Terms of gynecology and pediatrics in internal medicine of traditional Chinese medicine[J]. China Terminol, 2011, 13( 5): 63- 64. 全国科学技术名词审定委员会. 中医内科妇科儿科名词[J]. 中国科技术语, 2011, 13( 5): 63- 64.
[14]	GE BJ, ZHOU Y, XIAO TG, et al. The effect of Xiaoyao Powder combined with entecavir on fibrosis and iron metabolism in the treatment of liver depression and spleen deficiency type of compensated stage of hepatitis B cirrhosis[J]. J Hunan Univ Chin Med, 2021, 41( 2): 296- 302. DOI: 10.3969/j.issn.1674-070X.2021.02.025. 葛冰景, 周薏, 肖铁刚, 等. 逍遥散联合恩替卡韦对肝郁脾虚型乙型肝炎肝硬化代偿期患者纤维化及铁代谢的影响[J]. 湖南中医药大学学报, 2021, 41( 2): 296- 302. DOI: 10.3969/j.issn.1674-070X.2021.02.025.
[15]	GE BJ, XIAO TG, ZHOU Y, et al. Clinical study on Xiaoyao Powder combined with entecavir in the treatment of 30 cases of compensatory cirrhosis after hepatitis B with liver depression and spleen deficiency[J]. Jiangsu J Tradit Chin Med, 2020, 52( 11): 28- 31. DOI: 10.19844/j.cnki.1672-397X.2020.11.010. 葛冰景, 肖铁刚, 周薏, 等. 逍遥散联合恩替卡韦治疗肝郁脾虚型乙肝后肝硬化代偿期30例临床研究[J]. 江苏中医药, 2020, 52( 11): 28- 31. DOI: 10.19844/j.cnki.1672-397X.2020.11.010.
[16]	DAN LJ, WANG TY, HAO YW, et al. Meta-Analysis of Ganshuang Granules combined with nucleoside(acid) drugs treating chronic hepatitis B liver fibrosis[J]. Pharmacol Clin Chin Mater Med, 2020, 36( 5): 167- 172. DOI: 10.13412/j.cnki.zyyl.2020.05.019. 淡丽娟, 王天媛, 郝彦伟, 等. 肝爽颗粒联合核苷(酸)类药物治疗慢性乙型肝炎肝纤维化的Meta分析[J]. 中药药理与临床, 2020, 36( 5): 167- 172. DOI: 10.13412/j.cnki.zyyl.2020.05.019.
[17]	YANG QY, ZHAO SW. Observation on the effect of Yinchenhao Decoction on chronic hepatitis B[J]. Pract Clin J Integr Tradit Chin West Med, 2021, 21( 10): 11- 12. DOI: 10.13638/j.issn.1671-4040.2021.10.003. 杨庆宇, 赵松伟. 茵陈蒿汤应用于慢性乙型病毒性肝炎的效果观察[J]. 实用中西医结合临床, 2021, 21( 10): 11- 12. DOI: 10.13638/j.issn.1671-4040.2021.10.003.
[18]	YANG ZZ, CHENG ZW, XIE DM, et al. Modified Yinchenhao Decoction in treating 40 cases of liver fibrosis of chronic hepatitis B with damp-heat type[J]. Zhejiang J Tradit Chin Med, 2012, 47( 8): 559- 560. DOI: 10.3969/j.issn.0411-8421.2012.08.009. 杨壮智, 程志文, 谢冬梅, 等. 茵陈蒿汤加味治疗湿热型慢性乙型肝炎肝纤维化40例[J]. 浙江中医杂志, 2012, 47( 8): 559- 560. DOI: 10.3969/j.issn.0411-8421.2012.08.009.
[19]	LI GY, LI SM, CHEN YX, et al. Meta-analysis of Qianggan capsule for serum liver fibrosis markers of chronic hepatitis[J]. Liaoning J Tradit Chin Med, 2016, 43( 5): 900- 904. DOI: 10.13192/j.issn.1000-1719.2016.05.002. 黎桂玉, 李树民, 陈永欣, 等. 强肝胶囊对慢性肝炎血清肝纤维化指标作用的Meta分析[J]. 辽宁中医杂志, 2016, 43( 5): 900- 904. DOI: 10.13192/j.issn.1000-1719.2016.05.002.
[20]	CHEN ZB, YAO QJ. Dangfeiliganning capsule combined with entecavir in the treatment of 36 cases of chronic hepatitis B liver fibrosis[J]. Chin J Integr Tradit West Med Liver Dis, 2015, 25( 1): 55- 56. DOI: 10.3969/j.issn.1005-0264.2015.01.020. 陈焯彬, 姚钦江. 当飞利肝宁胶囊联合恩替卡韦治疗慢性乙型肝炎肝纤维化36例[J]. 中西医结合肝病杂志, 2015, 25( 1): 55- 56. DOI: 10.3969/j.issn.1005-0264.2015.01.020.
[21]	ZHANG GD, HUAN J, ZHU YB, et al. Effect of Dangfei Liganning capsule combined with interferon on serum levels of SII, NLR, PLR and MLR in patients with chronic hepatitis B liver fibrosis[J]. Chin Arch Tradit Chin Med, 2022, 40( 4): 183- 186. DOI: 10.13193/j.issn.1673-7717.2022.04.041. 张国栋, 郇娟, 朱英斌, 等. 当飞利肝宁胶囊联合干扰素对慢性乙型肝炎肝纤维化血清SII、NLR、PLR、MLR水平的影响[J]. 中华中医药学刊, 2022, 40( 4): 183- 186. DOI: 10.13193/j.issn.1673-7717.2022.04.041.
[22]	CAI XM, LI ZQ. Treating 36 cases of chronic hepatitis B liver fibrosis with dangfeiliganning capsule[J]. Chin J Integr Tradit West Med Dig, 2006, 14( 6): 408- 409. DOI: 10.3969/j.issn.1671-038X.2006.06.023. 蔡晓明, 李正秋. 当飞利肝宁胶囊治疗慢性乙型肝炎肝纤维化36例[J]. 中国中西医结合消化杂志, 2006, 14( 6): 408- 409. DOI: 10.3969/j.issn.1671-038X.2006.06.023.
[23]	JI MY, CHU WM. Clinical observation of dangfeiliganning combined with entecavir in the treatment of chronic hepatitis B[J]. Mod J Integr Tradit Chin West Med, 2014, 23( 1): 67- 68. DOI: 10.3969/j.issn.1008-8849.2014.01.027. 季旻游, 褚卫明. 当飞利肝宁联合恩替卡韦治疗慢性乙型肝炎临床观察[J]. 现代中西医结合杂志, 2014, 23( 1): 67- 68. DOI: 10.3969/j.issn.1008-8849.2014.01.027.
[24]	LAI TT, LU JL. Effect of dangfeiliganning tablets combined with tenofovir dipivoxil fumarate tablets on hepatic fibrosis of chronic hepatitis B[J]. Chin J Rural Med Pharm, 2021, 28( 20): 34- 35. DOI: 10.19542/j.cnki.1006-5180.005628. 赖婷婷, 陆佳林. 当飞利肝宁片联合富马酸替诺福韦二吡呋酯片对慢性乙肝肝纤维化的影响[J]. 中国乡村医药, 2021, 28( 20): 34- 35. DOI: 10.19542/j.cnki.1006-5180.005628.
[25]	ZHAO ZZ, LIU XD, LYU P, et al. Meta analysis of curative effect and safety of Gexia Zhuyu Decoction combined with nucleoside drugs in the treatment of hepatitis B cirrhosis[J]. Chin Arch Tradit Chin Med, 2019, 37( 3): 643- 649. DOI: 10.13193/j.issn.1673-7717.2019.03.031. 赵壮志, 刘旭东, 吕萍, 等. 膈下逐瘀汤加减联合核苷类药物治疗乙型肝炎肝硬化疗效及安全性的Meta分析[J]. 中华中医药学刊, 2019, 37( 3): 643- 649. DOI: 10.13193/j.issn.1673-7717.2019.03.031.
[26]	WANG T, ZHOU X, LIU H, et al. Fuzheng Huayu capsule as an adjuvant treatment for HBV-related cirrhosis: A systematic review and meta-analysis[J]. Phytother Res, 2018, 32( 5): 757- 768. DOI: 10.1002/ptr.6009.
[27]	MENG XB, PAN ZQ, ZHAO JW, et al. Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: A systematic review and meta-analysis[J]. Medicine(Baltimore), 2022, 101( 46): e31664. DOI: 10.1097/MD.0000000000031664.
[28]	ZHANG YX, SUN FX, LI XL. Systematic review of Anluo Huaxian pills combined with entecavir in the treatment of hepatitis B-related liver cirrhosis[J]. Eval Anal Drug-Use in Hosp China, 2022, 22( 1): 70- 76, 82. DOI: 10.14009/j.issn.1672-2124.2022.01.015. 张莹雪, 孙凤霞, 李晓玲. 安络化纤丸联合恩替卡韦治疗乙型肝炎肝硬化的系统评价[J]. 中国医院用药评价与分析, 2022, 22( 1): 70- 76, 82. DOI: 10.14009/j.issn.1672-2124.2022.01.015.
[29]	WANG Y, ZHONG S, CHEN J. Heluo Shugan capsule for liver fibrosis of chronic hepatitis B: A systematic review[J]. Chin J Evid-Based Med, 2016, 16( 8): 962- 971. DOI: 10.7507/1672-2531.20160148. 王元, 钟森, 陈婧. 和络舒肝胶囊治疗乙型肝炎肝纤维化疗效的系统评价[J]. 中国循证医学杂志, 2016, 16( 8): 962- 971. DOI: 10.7507/1672-2531.20160148.
[30]	QIN XQ, CHEN Y, WU WQ, et al. Clinical curative effect of nine kinds of Gantai capsule combined with entecavir in treatment of chronic hepatitis B cirrhosis[J]. Chin J Integr Tradit West Med Liver Dis, 2016, 26( 6): 361- 363, 376. DOI: 10.3969/j.issn.1005-0264.2016.06.015. 秦雪琴, 陈悦, 吴文琴, 等. 九味肝泰胶囊联合恩替卡韦治疗慢性乙型肝炎肝硬化的临床疗效观察[J]. 中西医结合肝病杂志, 2016, 26( 6): 361- 363, 376. DOI: 10.3969/j.issn.1005-0264.2016.06.015.
[31]	DUAN SH, BAO ZY, YUAN XD, et al. Efficacy observation of yiguanjian decoction combined adefovir dipivoxil tablet in treating HBe Ag negative chronic viral hepatitis B active compensated liver cirrhosis patients[J]. Chin J Integr Tradit West Med, 2016, 36( 5): 535- 538. DOI: 10.7661/CJIM.2016.05.0535. 段淑红, 鲍中英, 苑晓冬, 等. 一贯煎加味联合阿德福韦酯片治疗HBeAg阴性慢性乙型肝炎活动性代偿期肝硬化患者的疗效观察[J]. 中国中西医结合杂志, 2016, 36( 5): 535- 538. DOI: 10.7661/CJIM.2016.05.0535.
[32]	HOU MT, DING KX, HE TT, et al. Meta-analysis of efficacy and safety of Liuwei Wuling Tablets combined with conventional drugs in treatment of liver fibrosis and cirrhosis in chronic hepatitis B[J]. China J Chin Mater Med, 2022, 47( 1): 224- 234. DOI: 10.19540/j.cnki.cjcmm.20210728.501. 侯曼婷, 丁凯欣, 何婷婷, 等. 六味五灵片联合常规药物治疗慢性乙型肝炎肝纤维化及肝硬化有效性和安全性的Meta分析[J]. 中国中药杂志, 2022, 47( 1): 224- 234. DOI: 10.19540/j.cnki.cjcmm.20210728.501.
[33]	SUO CY, CUI XQ, LI YF, et al. Clinical observation of entecavir combined with Xinganbao capsule in the treatment of chronic hepatitis B liver fibrosis[J]. Mod J Integr Tradit Chin West Med, 2019, 28( 12): 1339- 1342. DOI: 10.3969/j.issn.1008-8849.2019.12.024. 索成云, 崔向青, 李艳芬, 等. 恩替卡韦联合心肝宝胶囊治疗慢性乙型肝炎肝纤维化疗效观察[J]. 现代中西医结合杂志, 2019, 28( 12): 1339- 1342. DOI: 10.3969/j.issn.1008-8849.2019.12.024.
[34]	GAO YZ, JIA SH, ZHAO LF, et al. Clinical efficacy of entecavir combined with Xinganbao capsules in treatment of liver cirrhosis among patients with chronic hepatitis B[J]. J Clin Hepatol, 2014, 30( 4): 314- 316. DOI: 10.3969/j.issn.1001-5256.2014.04.007. 高远征, 贾素华, 赵连峰, 等. 恩替卡韦联合心肝宝胶囊治疗慢性乙型肝炎肝硬化的疗效观察[J]. 临床肝胆病杂志, 2014, 30( 4): 314- 316. DOI: 10.3969/j.issn.1001-5256.2014.04.007.
[35]	WANG XB, JIANG YY, ZHAO CY, et al. Clinical research of Xinganbao capsule on the treatment of chronic hepatitis B liver fibrosis[J]. Chin J Integr Tradit West Med, 2012, 32( 3): 325- 328. 王宪波, 江宇泳, 赵彩彦, 等. 心肝宝胶囊治疗慢性乙型肝炎肝纤维化临床研究[J]. 中国中西医结合杂志, 2012, 32( 3): 325- 328.
[36]	WANG XM, ZHANG W. Clinical observation on anti-hepatic fibrosis of Xinganbao capsule[J]. China Pract Med, 2009, 4( 34): 129- 130. DOI: 10.3969/j.issn.1673-7555.2009.34.099. 王喜梅, 张威. 心肝宝胶囊抗肝纤维化的临床观察[J]. 中国实用医药, 2009, 4( 34): 129- 130. DOI: 10.3969/j.issn.1673-7555.2009.34.099.
[37]	CHEN LY. Observation on therapeutic effect of magnesium isoglycyrrhizinate combined with Xinganbao capsule on chronic hepatitis B[J]. Proceeding Clin Med, 2009, 18( 6): 130- 131. 陈龙岩. 异甘草酸镁联合心肝宝胶囊治疗慢性乙型肝炎疗效观察[J]. 临床医药实践, 2009, 18( 6): 130- 131.
[38]	Branch of Gastrointestinal Diseases, China Association of Chinese Medicine. Expert consensus on TCM diagnosis and treatment of ascites due to cirrhosis(2017)[J]. J Clin Hepatol, 2017, 33( 9): 1621- 1626. DOI: 10.3969/j.issn.1001-5256.2017.09.002. 中华中医药学会脾胃病分会. 肝硬化腹水中医诊疗专家共识意见(2017)[J]. 临床肝胆病杂志, 2017, 33( 9): 1621- 1626. DOI: 10.3969/j.issn.1001-5256.2017.09.002.
[39]	Drafting group of“guideline for diagnosis and treatment of hepatorenal syndrome in Traditional Chinese Medicine(Revised)”. Guideline to clinical diagnosis and treatment of Traditional Chinese Medicine: Hepatorenal syndrome(Revised Version)[J]. Chin J Integr Trad West Med Dig, 2022, 30( 7): 461- 468. DOI: 10.3969/j.issn.1671-038X.2022.07.01. 《中医内科诊疗指南·肝肾综合征(修订)》起草组. 中医内科临床诊疗指南·肝肾综合征(修订版)[J]. 中国中西医结合消化杂志, 2022, 30( 7): 461- 468. DOI: 10.3969/j.issn.1671-038X.2022.07.01.
[40]	MENG YH, LI JT, LIU JH, et al. Meta-analysis on Wulin Powder in treating cirrhotic ascites[J]. Guid J Tradit Chin Med Pharm, 2020, 26( 3): 43- 46. DOI: 10.13862/j.cnki.cn43-1446/r.2020.03.011. 孟宇航, 李京涛, 刘佳昊, 等. 五苓散加减治疗肝硬化腹水的Meta分析[J]. 中医药导报, 2020, 26( 3): 43- 46. DOI: 10.13862/j.cnki.cn43-1446/r.2020.03.011.
[41]	WEI YQ, MENG L, MENG ZR, et al. A Meta analysis of spleen-strengthening decoction in the treatment of ascites due to cirrhosis[J]. Henan Tradit Chin Med, 2021, 41( 2): 236- 244. DOI: 10.16367/j.issn.1003-5028.2021.02.0057. 魏益谦, 孟靓, 孟智睿, 等. 实脾饮治疗肝硬变腹水Meta分析[J]. 河南中医, 2021, 41( 2): 236- 244. DOI: 10.16367/j.issn.1003-5028.2021.02.0057.
[42]	GAN DN, DU HB, CHI XL, et al. Study on the clinical effects and safety of Yiqi Huoxue Decoction on qi deficiency and blood stasis syndrome hepatocirrhosis with ascites in hepatitis B[J]. World Chin Med, 2018, 13( 12): 2980- 2986. DOI: 10.3969/j.issn.1673-7202.2018.12.007. 甘大楠, 杜宏波, 池晓玲, 等. 自拟益气活血方治疗乙肝肝硬化腹水气虚血瘀证临床疗效与安全性研究[J]. 世界中医药, 2018, 13( 12): 2980- 2986. DOI: 10.3969/j.issn.1673-7202.2018.12.007.
[43]	ZHAO WX, ZHANG LH, LIANG HW. Clinical study of Jianpi Bushen Lishui Recipe on reducing ascites volume in patients with ascites due to cirrhosis[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29( 1): 23- 25. DOI: 10.3969/j.issn.1005-0264.2019.01.008. 赵文霞, 张丽慧, 梁浩卫. 健脾补肾利水方降低肝硬化腹水患者腹水量的临床研究[J]. 中西医结合肝病杂志, 2019, 29( 1): 23- 25. DOI: 10.3969/j.issn.1005-0264.2019.01.008.
[44]	ZHOU Y, XING F, ZHAO CQ, et al. Clinical observation on treatment of refractory ascites in liver cirrhosis by modified Tuduzi Buqi Decoction combined with western medicine conventional therapy[J]. Shanghai J Tradit Chin Med, 2021, 55( 5): 67- 69, 76. DOI: 10.16305/j.1007-1334.2021.2011059. 周扬, 邢枫, 赵长青, 等. 徒都子补气汤加减联合西医常规疗法治疗肝硬化顽固性腹水的临床观察[J]. 上海中医药杂志, 2021, 55( 5): 67- 69, 76. DOI: 10.16305/j.1007-1334.2021.2011059.
[45]	LUO XL, GUAN W, GOU CY, et al. Clinical observation of nourishing kidney and softening liver in treating refractory ascites due to liver and kidney Yin deficiency[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29( 3): 214- 216. DOI: 10.3969/j.issn.1005-0264.2019.03.007. 罗晓岚, 关伟, 勾春燕, 等. 滋肾柔肝法治疗肝肾阴虚型肝硬化顽固性腹水临床观察[J]. 中西医结合肝病杂志, 2019, 29( 3): 214- 216. DOI: 10.3969/j.issn.1005-0264.2019.03.007.
[46]	HAN D. Traditional Chinese medicine combined with western medicine for spontaneous bacterial peritonitis in cirrhosis: Systematic review and Meta-analysis[D]. Shenyang: Liaoning University of Traditional Chinese Medicine, 2018. 韩丹. 中药联合西药治疗肝硬化自发性细菌性腹膜炎: 系统评价及Meta分析[D]. 沈阳: 辽宁中医药大学, 2018.
[47]	LI T, XU CJ, LI SD, et al. Meta-analysis of umbilical therapy for the treatment of cirrhosis ascites[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29( 6): 533- 538. DOI: 10.3969/j.issn.1005-0264.2019.06.018. 李婷, 徐春军, 李尚点, 等. 脐疗辅助治疗肝硬化腹水的Meta分析[J]. 中西医结合肝病杂志, 2019, 29( 6): 533- 538. DOI: 10.3969/j.issn.1005-0264.2019.06.018.
[48]	XING F, TAN Y, YAN GJ, et al. Effects of Chinese herbal cataplasm Xiaozhang Tie on cirrhotic ascites[J]. J Ethnopharmacol, 2012, 139( 2): 343- 349. DOI: 10.1016/j.jep.2011.10.040.
[49]	ZHU JF, WANG LT. Clinical research of“Shuigu Cataplasm” umbilical compressing combined with Tolvaptan in treatment of refractory cirrhosis ascites[J]. Shanghai J Tradit Chin Med, 2016, 50( 4): 37- 40. DOI: 10.16305/j.1007-1334.2016.04.012. 祝峻峰, 王灵台.“水臌贴” 敷脐联合托伐普坦等治疗慢性乙型肝炎肝硬化顽固性腹水的临床研究[J]. 上海中医药杂志, 2016, 50( 4): 37- 40. DOI: 10.16305/j.1007-1334.2016.04.012.
[50]	GAO SC, XIA L, ZHAO G, et al. Combination of ascites cataplasm and western medicine for ascites due to liver cirrhosis of spleen and kidney Yang deficiency pattern: A randomized placebo-controlled trial[J]. Shanghai J Tradit Chin Med, 2015, 49( 2): 28- 30, 33. DOI: 10.16305/j.1007-1334.2015.02.027. 高司成, 夏莉, 赵钢, 等.“水臌贴” 敷脐联合西药治疗脾肾阳虚型肝硬化腹水随机安慰剂对照临床研究[J]. 上海中医药杂志, 2015, 49( 2): 28- 30, 33. DOI: 10.16305/j.1007-1334.2015.02.027.
[51]	XIAO DH, GU J, CAI H, et al. A randomized placebo-controlled multicentre study of Fuzhenghuayu capsule for prevention of oesophageal variceal bleeding in patients with liver cirrhosis[J]. Chin J Hepatol, 2014, 22( 8): 594- 599. DOI: 10.3760/cma.j.issn.1007-3418.2014.08.009. 肖定洪, 顾杰, 蔡虹, 等. 扶正化瘀胶囊预防肝硬化患者食管静脉曲张破裂出血的随机对照多中心临床研究[J]. 中华肝脏病杂志, 2014, 22( 8): 594- 599. DOI: 10.3760/cma.j.issn.1007-3418.2014.08.009.
[52]	ZHANG B. A study on the clinical efficacy of FFBJRGP and Propranolol combination therapy in preventing esophageal varices bleeding[J]. J Qiqihar Univ Med, 2015, 36( 27): 4066- 4067. 张博. 复方鳖甲软肝片联合普萘洛尔预防食管静脉曲张出血的疗效观察[J]. 齐齐哈尔医学院学报, 2015, 36( 27): 4066- 4067.
[53]	YUAN Y, WANG LJ, XUE BY. Effect of modified Gualou Powder on VEGF and hemodynamics of patients with PHT[J]. J Emerg Tradit Chin Med, 2012, 21( 5): 698- 699, 716. DOI: 10.3969/j.issn.1004-745X.2012.05.006. 袁渊, 王陆军, 薛博瑜. 加味瓜蒌散对肝硬化门静脉高压症患者血管内皮生长因子及血流动力学的影响[J]. 中国中医急症, 2012, 21( 5): 698- 699, 716. DOI: 10.3969/j.issn.1004-745X.2012.05.006.
[54]	XU XQ, LI M, CAO WJ, et al. Effect of Jiaweigualou Powder on blood gastrointestinal hormone, indexes of hepatic fibrosis and hemodynamics in patients with portal hypertention[J]. Chin J Integr Tradit West Med Liver Dis, 2009, 19( 2): 70- 72. DOI: 10.3969/j.issn.1005-0264.2009.02.003. 徐晓琦, 李民, 曹卫菊, 等. 加味瓜蒌散对肝硬化门静脉高压症患者胃肠激素、肝纤维化指标和血流动力学的影响[J]. 中西医结合肝病杂志, 2009, 19( 2): 70- 72. DOI: 10.3969/j.issn.1005-0264.2009.02.003.
[55]	HOU YX, ZHANG Q, YU H, et al. Randomized controlled study of Jianpi Huashi Zhixue Prescription on secondary prevention of esophagogastric variceal bleeding in patients with hepatitis B cirrhosis[J]. Beijing J Tradit Chin Med, 2022, 41( 2): 107- 112. DOI: 10.16025/j.1674-1307.2022.02.001. 侯艺鑫, 张群, 于浩, 等. 健脾化湿止血方对乙肝肝硬化食管胃静脉曲张破裂出血患者二级预防的随机对照研究[J]. 北京中医药, 2022, 41( 2): 107- 112. DOI: 10.16025/j.1674-1307.2022.02.001.
[56]	LI JF, LUO TC, AN ZX. A Meta analysis of treating hepatic encephalopathy with An'gong Niuhuang Wan with western medicine[J]. Clin J Chin Med, 2020, 12( 35): 142- 145. DOI: 10.3969/j.issn.1674-7860.2020.35.048. 李金芳, 罗天赐, 安祯祥. 安宫牛黄丸联合西药治疗肝性脑病的Meta分析[J]. 中医临床研究, 2020, 12( 35): 142- 145. DOI: 10.3969/j.issn.1674-7860.2020.35.048.
[57]	CUI YY, CHEN PL, CHEN ZY, et al. Meta-analysis of effects of Xingnaojing injection with ornithine aspartate on hepatic encephalopathy[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31( 9): 822- 827, 834. DOI: 10.3969/j.issn.1005-0264.2021.09.014. 崔亚运, 陈鹏兰, 陈梓洋, 等. 醒脑静联合门冬氨酸鸟氨酸治疗肝性脑病患者疗效的Meta分析[J]. 中西医结合肝病杂志, 2021, 31( 9): 822- 827, 834. DOI: 10.3969/j.issn.1005-0264.2021.09.014.
[58]	LIAO BL, ZHU JF, WANG LT, et al. Clinical study on Xinqingkai Decoction in preventing and treating chronic HBV infection-induced liver cirrhosis complicated with mild hepatic encephalopathy[J]. Shanghai J Tradit Chin Med, 2021, 55( 2): 63- 67. DOI: 10.16305/j.1007-1334.2021.2001101. 廖冰灵, 祝峻峰, 王灵台, 等. 新清开方防治慢性乙型肝炎后肝硬化合并轻微型肝性脑病的临床研究[J]. 上海中医药杂志, 2021, 55( 2): 63- 67. DOI: 10.16305/j.1007-1334.2021.2001101.
[59]	JIANG TT, YANG ZY, WANG XB, et al. Clinical efficacy of Yiqi Yangyin Jiedu Huayu formula modifications combined with western medicine in the treatment of minimal hepatic encephalopathy based on the stroop test[J]. J Tradit Chin Med, 2023, 64( 5): 490- 497. DOI: 10.13288/j.11-2166/r.2023.05.011. 姜婷婷, 杨志云, 王宪波, 等. 基于Stroop测试探讨益气养阴解毒化瘀方加减联合西药治疗轻微型肝性脑病的临床疗效[J]. 中医杂志, 2023, 64( 5): 490- 497. DOI: 10.13288/j.11-2166/r.2023.05.011.
[60]	PANG D, YAO C, FU L, et al. Meta-analysis of therapeutic effect of rhubarb decoction retention enema on hepatic encephalopathy[J]. Hunan J Tradit Chin Med, 2020, 36( 7): 127- 132. DOI: 10.16808/j.cnki.issn1003-7705.2020.07.054. 庞娣, 姚春, 付蕾, 等. 大黄煎剂保留灌肠治疗肝性脑病疗效的Meta分析[J]. 湖南中医杂志, 2020, 36( 7): 127- 132. DOI: 10.16808/j.cnki.issn1003-7705.2020.07.054.
[61]	XIAO Q, ZHANG Y, TAN SZ. The treatment by warming the kidney and promoting diuresis with Alprostadil in liver cirrhosis complicated with hepato-renal syndrome in 29 cases[J]. J Clin Hepatol, 2012, 28( 3): 189- 191. DOI: 10.3969/j.issn.1001-5256.2012.03.008. 肖倩, 张旸, 谭善忠. 温肾利水法联合前列地尔治疗肝硬化并发肝肾综合征29例[J]. 临床肝胆病杂志, 2012, 28( 3): 189- 191. DOI: 10.3969/j.issn.1001-5256.2012.03.008.
[62]	Nephrology Committee of Chinese Association of Integrative Medicine Committee of Chinese Medicine; Development and Research for Kidney Disease of China Association of Traditional Medicine. Consensus on application of Shenkang preparation(Shenkang injection and Shenkang suppository) in treatment of chronic kidney disease[J]. Chin J Integr Tradit West Med, 2019, 39( 7): 784- 786. DOI: 10.7661/j.cjim.20190520.017. 中国中西医结合学会肾脏疾病专业委员会, 中国中药协会肾病中药发展研究专业委员会. 肾康制剂(肾康注射液、肾康栓)治疗慢性肾脏病合理应用专家共识[J]. 中国中西医结合杂志, 2019, 39( 7): 784- 786. DOI: 10.7661/j.cjim.20190520.017.
[63]	LI D, FENG AQ, ZHANG YQ, et al. Clinical effect of Shenkang injection on hepatorenal syndrome[J]. Strait Pharm J, 2017, 29( 1): 139- 140. DOI: 10.3969/j.issn.1006-3765.2017.01.071. 李丹, 冯爱桥, 张瑜琪, 等. 肾康注射液应用于肝肾综合征的临床效果观察[J]. 海峡药学, 2017, 29( 1): 139- 140. DOI: 10.3969/j.issn.1006-3765.2017.01.071.